# Daniele Santini
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/daniele-santini/
## Facts
| Field | Value |
| --- | --- |
| Citations | 33,096 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 87 |
| i10-index | 521 |
| Last Known Institution | Policlinico Umberto I |
| OpenAlex ID | https://openalex.org/A5091765229 |
| ORCID iD | https://orcid.org/0000-0002-9118-3337 |
| Works | 1,339 |
## Researcher papers
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan](https://scholariq.org/papers/rechallenge-for-patients-with-i-ras-i-and-i-braf-i-wild-type-metastatic/)
- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer](https://scholariq.org/papers/pten-expression-and-kras-mutations-on-primary-tumors-and-metastases-in-the/)
- [Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.](https://scholariq.org/papers/pamidronate-induces-modifications-of-circulating-angiogenetic-factors-in-cancer/)
- [Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice](https://scholariq.org/papers/integrated-analysis-of-concomitant-medications-and-oncological-outcomes-from-pd/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients](https://scholariq.org/papers/correlations-between-the-immune-related-adverse-events-spectrum-and-efficacy-of/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)
## Researcher topics
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
## Researcher university
- [Policlinico Umberto I](https://scholariq.org/institutions/policlinico-umberto-i/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.